TWST Stock: Price, Earnings History and SEC Filings
Twist Bioscience Corporation (TWST) last traded at $152.78, down 11.92% on the latest session and down 20.9% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.56 against an analyst estimate of $-0.50, a miss of 12.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
TWST earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 3, 2026 | $-0.56 | $-0.50 | -12.00% |
| Mar 2026 | May 4, 2026 | $-0.62 | $-0.54 | -14.81% |
| Dec 2025 | Feb 2, 2026 | $-0.50 | $-0.48 | -4.17% |
| Sep 2025 | Nov 14, 2025 | $-0.45 | $-0.40 | -12.50% |
TWST beat the analyst EPS estimate in 0 of its last 4 reported quarters. Source: Nasdaq.
How TWST reacts to earnings
Across its last 8 earnings releases, TWST moved 8.6% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-03 | Before open | +10.39% |
| 2026-05-04 | Before open | -6.97% |
| 2026-02-02 | Before open | +13.98% |
| 2026-01-12 | Before open | +7.70% |
| 2025-11-14 | Before open | -10.13% |
| 2025-08-04 | Before open | -10.30% |
| 2025-05-05 | Before open | -8.44% |
| 2025-02-03 | Before open | +0.73% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
TWST financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $377M | -$78M | -$76M | -20.6% | $-1.30 |
| 2024 | $313M | -$209M | -$69M | -66.7% | $-3.60 |
| 2023 | $245M | -$205M | -$170M | -83.5% | $-3.60 |
| 2022 | $204M | -$218M | -$226M | -107.0% | $-4.04 |
| 2021 | $132M | -$152M | -$139M | -114.9% | $-3.15 |
| 2020 | $90M | -$140M | -$152M | -155.3% | $-3.57 |
| 2019 | $54M | -$108M | -$103M | -198.0% | – |
| 2018 | $25M | -$71M | -$70M | -280.2% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for TWST
- 8-K · Aug 19, 2026Other events, Financial statements and exhibits
- 424B7 · Aug 19, 2026
- 8-K · Aug 19, 2026Regulation FD disclosure
- 8-K · Aug 5, 2026Material agreement, Regulation FD disclosure, Financial statements and exhibits
- 424B5 · Aug 5, 2026
- 424B5 · Aug 4, 2026
- 10-Q · Aug 3, 2026
- 8-K · Aug 3, 2026Results of operations, Financial statements and exhibits
- 10-Q · May 4, 2026
- 8-K · May 4, 2026Results of operations, Financial statements and exhibits
Insider filing activity
TWST insiders filed 37 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
TWST news
- Global Gene Writing Technology Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 24.8% CAGR with Beam, Twist Bioscience, Tessera, and IntelliaOct 29, 2026 · finance.yahoo.com
- Long Oligo Pool Synthesis for Capture Global Market Report 2026 | Capitalize on $3.31B by 2030 as Twist Bioscience, Agilent, Eurofins and BGI Scale AI-Driven Precision OncologyOct 29, 2026 · finance.yahoo.com
- Robust Demand Across BioPharma and NGS Applications Elevates Twist Bioscience Corp.’s (TWST) Growth ProfileOct 29, 2026 · finance.yahoo.com
- Twist Bioscience Launches MRD Express with Rapid Turnaround TimeOct 29, 2026 · finance.yahoo.com
- Twist Bioscience Stock Gains Attention After Antibody Screening LaunchOct 29, 2026 · finance.yahoo.com
- Twist Bioscience Soars 12%, 10x Genomics Up 12% as Genomics Stocks ReboundOct 28, 2026 · tikr.com
- Absci Soars 12%, Schrödinger Up 11%, Recursion Up 9% as AI Drug Discovery Stocks RallyOct 28, 2026 · tikr.com
- Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening AntibodiesOct 28, 2026 · finance.yahoo.com
About Twist Bioscience Corporation
Twist Bioscience Corporation (TWST) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in September.